Opiant Pharma Starts Dosing In OPNT002 Mid-Stage Study For Alcohol Use Disorder 2 years ago [#item_full_content] Opiant Pharma’s Starts Dosing In Nasal Nalmefene Comparison Study For Remifentanil-Related Respiratory DepressionDateApril 6, 2021In relation toSimilar postOpiant Pharma Advances OPNT003 PK Study With First Patient DosingDateFebruary 9, 2021In relation toSimilar postAnnexon Shares Gain After Patient Dosing Starts In Mid-Stage Study For Vision Loss Disorder TherapyDateMarch 1, 2021In relation toSimilar post
